Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.

International journal of radiation oncology, biology, physics - 1 Aug 2017

Mistry Ishna N, Thomas Matthew, Calder Ewen D D, Conway Stuart J, Hammond Ester M

Abstract excerpt

With the increasing incidence of cancer worldwide, the need for specific, effective therapies is ever more urgent. One example of targeted cancer therapeutics is hypoxia-activated prodrugs (HAPs), also known as bioreductive prodrugs. These prodrugs are inactive in cells with normal oxygen levels but in hypoxic cells (with low oxygen levels) undergo chemical reduction to the active compound. Hypoxia is a common...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Molecular Targeted Therapy

Share to Neoplasm Proteins

Share to Neoplasms

Share to Prodrugs

Share to Radiation Tolerance

Source

Identifiers

PMID: 28721903
DOI: 10.1016/j.ijrobp.2017.03.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.PMID 28721903Read ↗

Systemic CYP3A inhibition by ritonavir enables selective targeting of hypoxic tumour cells by prodrugs of DNA-PK inhibitorsSemantic proximity Read ↗

Generation of Hydrogen Peroxide in Cancer Cells: Advancing Therapeutic Approaches for Cancer TreatmentSemantic proximity Read ↗

The impact of hypoxia and its modification of the outcome of radiotherapySemantic proximity Read ↗

GBM radiosensitizers: dead in the water…or just the beginning?Semantic proximity Read ↗

Photodynamic Therapy and Tumor Microenvironment-Targeting Strategies: A Novel Synergy at the Frontier of Cancer TreatmentSemantic proximity Read ↗

Synergistic Cytotoxicity Between Cold Atmospheric Plasma and Pyrazolopyrimidinones Against Glioblastoma CellsSemantic proximity Read ↗

Hydrogen and Vitamin C Combination Therapy: A Novel Method of RadioprotectionSemantic proximity Read ↗

Chemo-radiotherapy: radiosensitizing nucleoside analogues (review).Semantic proximity Read ↗

Therapeutic ultrasound enables rapid and robust activation of ROS-responsive prodrugs in vivoSemantic proximity Read ↗

Radiodynamic Therapy for High-Grade Glioma in Normoxic and Hypoxic Environments for High-Grade GliomaSemantic proximity Read ↗

Oxygen nanobubbles revert hypoxia by methylation programmingSemantic proximity Read ↗

An overview of targeted cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.